Zydus Lifesciences US arm wins USFDA nod for Levothyroxine Sodium for Injection to treat myxedema coma

The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.

Published On 2022-11-28 06:02 GMT | Update On 2022-11-28 06:04 GMT

Ahmedabad: Zydus Lifesciences Limited's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has recently announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Levothyroxine Sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial. Levothyroxine Sodium injection manufactured by Fresenius Kabi USA, LLC.

Myxedema coma is an extreme or decompensated form of hypothyroidism and, while uncommon, is potentially lethal. Primary symptoms of the disease are low body temperature and altered mental status.

Levothyroxine Sodium injection is indicated for the treatment of myxedema coma.

The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.

Levothyroxine Sodium injection had annual sales of USD 45.2 mn in the United States, according to IQVIA data (IQVIA MAT Sep 2022). The group now has 334 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the manufacture of generic drugs. Zydus group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim in India and in the US and Brazil.

Zydus' global business has a strong presence in the regulated markets of the US, Europe (France and Spain), and the high-profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Lifesciences US arm wins USFDA nod for Levothyroxine Sodium for Injection to treat myxedema coma

The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.

Similar News

Price Cap Exemption Pending: NPPA Refers Biodeal Pharma's Midazolam Nasal Spray to CDSCO, SNCM for Review

Zydus Gets CDSCO Panel Nod for Phase III Trial of Dextromethorphan, Phenylephrine Cough Syrup FDC

Toxic Coldrif Fallout: Tamil Nadu Govt Issues Show-Cause Notice to Sresan Pharma, License at Risk

Maharashtra B.Pharm Admissions 2025: 29,166 Students Allotted Seats in First Round

Zydus Lifesciences gets NOC from Health Canada for hypothyroidism tablets

Zydus Lifesciences secures USFDA okay for Duchenne Muscular Dystrophy drug

Coldrif Syrup banned in Maharashtra after child deaths

Sensitise public on alert against Coldrif cough syrup batch: Telangana govt directs health officials